4//SEC Filing
Reali Kenneth Michael 4
Accession 0000899243-23-008792
CIK 0001665988other
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 9:19 PM ET
Size
11.4 KB
Accession
0000899243-23-008792
Insider Transaction Report
Form 4
Reali Kenneth Michael
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
2023-03-15$1.39/sh−9,811$13,625→ 30,085 total - Award
Restricted Stock Units
2022-03-14+114,882→ 114,882 total→ Class A Common Stock (114,882 underlying) - Exercise/Conversion
Restricted Stock Units
2023-03-14−28,721→ 86,161 total→ Class A Common Stock (28,721 underlying) - Exercise/Conversion
Class A Common Stock
2023-03-14+28,721→ 39,896 total
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
- [F2]Reflects shares sold to cover taxes upon the vesting of the RSUs on March 14, 2023 pursuant to a standing 10b5-1 instruction.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.37 to $1.43, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The original grant of 114,882 RSUs vest in four approximately equal annual installments beginning on March 14, 2023.
Documents
Issuer
Bioventus Inc.
CIK 0001665988
Entity typeother
Related Parties
1- filerCIK 0001480801
Filing Metadata
- Form type
- 4
- Filed
- Mar 15, 8:00 PM ET
- Accepted
- Mar 16, 9:19 PM ET
- Size
- 11.4 KB